Richard Alan Furie, MD

Professor, Center for Autoimmune, Musculoskeletal and Hematopoietic Diseases,
The Feinstein Institute for Medical Research

Chief, Division of Rheumatology, Northwell Health

Professor of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

Phone: (516) 708-2550

About the Investigator

Dr. Richard Furie, Chief of the Division of Rheumatology at Northwell Health, is a rheumatologist whose activities for the last several decades have focused on patient care, physician education, and clinical research in the area of anti-rheumatic drug development. He directs The Program in Novel Therapeutics, the Health System’s clinical research program in musculoskeletal disease. He also directs the SLE and Autoimmune Disease Treatment Center, which has become internationally recognized for its role in the development of new therapies for SLE.

Regarded as one the senior rheumatologists in the New York metropolitan area, he has been on the Boards of Directors of the local chapters of the Arthritis Foundation and the Lupus Alliance of America and has been a member of the Medical-Scientific Advisory Council of the Lupus Foundation of America as well as its Lupus News editorial board. He also is on the Medical and Scientific Advisory Board of the SLE Foundation as well as the Alliance for Lupus Research Scientific Advisory Board.

Dr. Furie has served on many committees of the American College of Rheumatology, including the College’s Board of Directors. Although often featured as a speaker at national and international conferences, Dr. Furie’s favorite educational venue is at home with the Hofstra Northwell medical students and Northwell Health internal medicine residents.

Research Focus

Dr. Furie’s research focus has been in systemic lupus (SLE) and related diseases such as the antiphospholipid syndrome. Specifically, he has played an instrumental role in drug development and clinical trial design in SLE and lupus nephritis. Known as The Program in Novel Therapeutics, the division’s research program has established itself as a national and international leader in clinical trials.

Cornell University College of Arts and Sciences
Degree: AB

Cornell University Medical College
Degree: MD

The New York Hospital
Degree: Residency
Field of Study: Internal Medicine

The New York Hospital
Field of Study: Assistant Resident

Awards & Honors

2014 Arthritis Foundation Walk Honoree
2010 Long Island’s Top Doctors
2005 America’s Top Physicians
2002, 2010 New York Magazine Best Doctors
1999 Top Doctors: NY Metro Area
1997 Top Doctors: NY Metro Area
1982-1983 Fellow of the Arthritis Foundation
1981 Assistant Chief Resident, New York Hospital
1974 A.B. Magna cum laude

  1. Jacobi AM, Huang W, Wang T, Freimuth W, Sanz I, Furie R, Mackay M, Aranow C, Diamond B, Davidson A. “Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: Extension of a phase II, double-blind, placebo-controlled, dose-ranging study.” Arthritis Rheum 2010; 62(1): 201-210.
  2. Arad A, Proulle V, Furie RA, Furie BC, Furie B. “β2 glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model.” Blood 2011; 117(12): 3453-9.
  3. Merrill JT, Buyon JP, Furie RA, Latinis KM, Gordon C, Hsieh HJ, Brunetta P. “Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER).” Lupus. 2011; 20(7):709-16.
  4. Furie RA, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham W, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF. “A phase 3, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits BLyS, in patients with active systemic lupus erythematosus.” Arthritis Rheum 2011; 63(12):3918-3930.
  5. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, Maciuca R, Zhang D, Garg JP, Brunetta P, Appel G; for the LUNAR Investigator Group. “Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab (LUNAR) study.” Arthritis Rheum 2012; 64(4):1215-26.
  6. Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, Ginzler EM, D’Cruz DP, Doria A, Cooper S, Zhong ZJ, Hough D, Freimuth W, Petri MA. “Effects of belimumab, a B-lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase 3 trials.” Ann Rheum Dis 2012; [Epub ahead of print]
  7. Horowitz D, Furie R. “Does belimumab reduce disease activity in adults with systemic lupus erythematosus?” Clin Med Rev Ther 2012; 4:71-78.
  8. Horowitz D, Marder G, Furie R: “Musculoskeletal System: Articular Disease, Bone Metabolism in Systemic Lupus Erythematosus.” Edited by Lahita RG. New York, Elsevier, 2010.
  9. Bogachuk E, Furie R: “Systemic lupus erythematosus in Perioperative Management of the Patient with Rheumatic Disease.” Edited by Brian Mandell. Springer, in press.

View more at PubMed